Open Payments and Pharmaceutical Kickbacks: The Names Added to Dinner and the Names Left Off

Open Payments records industry payments that can help expose pharmaceutical kickbacks when connected to the events, prescribing decisions and government-paid claims behind them. If you reconcile speaker expenses, consulting fees or reportable recipients, you may know why the public entry tells only part of the story. A dinner can acquire attendees who never came. A physician who did attend can disappear from the expense report. The person reconciling those records sees something a payment total cannot explain.

What Open Payments Records

Open Payments makes manufacturers’ reported financial relationships with physicians, teaching hospitals and other covered healthcare practitioners public. The Physician Payments Sunshine Act requires covered manufacturers to report payments and other transfers of value annually. The records identify the recipient, amount, payment dates, form of payment and its nature, such as consulting, food and beverage, travel, education or speaking services. Where a payment relates to marketing, education or research about a covered product, the report also identifies the product.

Research payments and ownership interests appear separately from general payments. For someone working in finance or commercial operations, the category is the beginning of the comparison with what the business actually paid for.

The Centers for Medicare and Medicaid Services reported $82.24 billion in Open Payments for program years 2019 through 2025. That is the scale of disclosed financial relationships across the program. The attendance record explains a different part of the story: who actually received the benefit.

The reporting duty also reaches certain payments routed through someone else. When a manufacturer makes a transfer to another person or organization at a covered recipient’s request, or on that recipient’s behalf, it must disclose the transfer under the covered recipient’s name. The payee on the invoice and the recipient whose relationship must be disclosed can therefore be different.

The Payment Year and the Publication Year

The program year identifies the period covered by the payment data. Publication comes later. Public National Provider Identifiers first appeared in the program-year 2021 data released on June 30, 2022. Earlier public payment files required matching physician identities through other information to connect them with prescribing records.

Physician assistants, nurse practitioners, clinical nurse specialists, nurse anesthetists and nurse-midwives first appeared as covered recipients in program year 2021. Comparing an older payment file with a newer one means comparing different reporting populations.

How to Find Out If Your Doctor Is Getting Kickbacks From Pharmaceutical Companies?

Open Payments shows what manufacturers reported paying your doctor. To understand whether a payment bought prescribing or purchasing, we connect it to what the company expected in return and what happened inside the business.

For a speaker fee, that means the selection of the speaker, the audience, the presentation and the prescribing relationship. For consulting, it means the work commissioned, the work delivered and how the fee was set. The public amount gives a starting point. The records inside the business explain why that recipient received it.

Open Payments contains no prescription claims. Prescribing data and government payment records supply a separate part of the account. Matching the recipient to a prescriber connects identities. Event records, communications and the company’s selection decisions explain the commercial purpose of the payment.

A missing entry raises a different question: what reached the reporting system in the first place? Veloxis admitted that falsified expense reports fed its reports to the Centers for Medicare and Medicaid Services, causing it to underreport or fail to report the true payment amounts. A reconciliation can therefore begin with an expense the employee remembers and a recipient the public file never shows.

Where the Money Travels Outside the Payment File

Samples, discounts, rebates, in-kind patient educational materials and donations to charitable copay foundations fall outside the payment file. A foundation is not a covered recipient, so the public record of a physician’s payments leaves that money channel out.

What Is a Pharmaceutical Kickback?

Under the Anti-Kickback Statute, a pharmaceutical kickback is money or another benefit knowingly offered, paid, requested or received to induce or reward prescribing, referrals or purchasing involving federal health care program business. The benefit can be a speaking fee, a meal or a payment through an intermediary. The commercial purpose connects the benefit to the business the manufacturer wants.

When claims resulting from that conduct reach a government program, the False Claims Act can reach the company that caused them. The manufacturer may arrange the payment while a pharmacy or physician submits the drug claim. Following the transaction through those different participants is central to the case.

How Do Pharmaceutical Kickbacks Work?

In a speaker-program scheme, a manufacturer uses the fee and hospitality attached to an educational event to buy prescribing. The paperwork describes a talk. The sales decisions reveal why that doctor was paid.

The HHS Office of Inspector General’s November 2020 speaker-program alert identified circumstances worth examining together: little substantive information, repeated presentations without new information, repeat attendees, people without a reason to attend, expensive meals and unsuitable venues. It also identified speaker selection influenced by sales or expected revenue and compensation tied to business generated or set above fair market value.

Those details connect the event to its intended audience and commercial purpose. Why did the same doctors keep attending the same presentation? Why did prescribing volume determine who received speaking opportunities? Why did a speaker receive a fee when the presentation never happened? The expense category alone cannot answer those questions.

Veloxis Added Attendees and Omitted Physicians

Veloxis’s expense reports concealed payments by changing who supposedly attended. In the criminal case described in the Justice Department’s August 2026 resolution announcement, the company admitted under its deferred prosecution agreement that employees added names to event lists to lower the apparent meal cost per attendee. In the same agreement, it admitted that employees omitted physicians who attended to avoid Sunshine Act reporting.

The manipulation Veloxis admitted in its criminal case worked in opposite directions. More names made a costly meal look cheaper per person. Fewer physician names kept actual recipients out of the disclosure process. The dinner bill remained, while the records changed who appeared to benefit from it.

Veloxis’s reports to the Centers for Medicare and Medicaid Services relied on those falsified expense reports. The company consequently underreported or failed to report the true payment amounts. The public disclosure inherited the false attendance record inside the business.

The company agreed to a separate $1.55 million Open Payments civil penalty from the Centers for Medicare and Medicaid Services. Its civil False Claims Act and state resolution was $34.45 million. The reporting penalty and the civil claims settlement addressed different parts of the conduct. An expense report sat at the connection between them.

The Attendance Pattern Appears Elsewhere

Salix admitted that sales representatives reported physicians as attending events they had missed to make the per-person meal cost appear lower and evade meal-cost limits. In the 2016 civil settlement, its admissions also described prerecorded presentations left unplayed, placed where attendees could not readily see or hear them, and speaker fees paid even when the required call to the speaker never happened. The supposed educational event survived in the paperwork after the education disappeared.

A separate whistleblower complaint about Novartis’s Gilenya programs alleged that verbal reservations allowed canceled or under-attended events to generate speaker payments:

The complaint puts the attendance record at the payment decision. An employee who knows the event was canceled can explain why an apparently complete payment file tells the wrong story.

Do Doctors Still Get Kickbacks From Pharmaceutical Companies?

Yes. Recent civil resolutions describe payments intended to influence prescribing. Gilead agreed to a 2025 civil settlement over its HIV speaker programs and admitted facts about payments to high-volume prescribers and repeated attendance. Its admissions included doctors attending multiple dinners on the same topic within a short period.

Gilead also admitted that one paid speaker’s prescriptions generated payments from Medicare, Medicaid and TRICARE. That connection matters to the employee looking beyond the expense account. The meal and speaking fee begin the transaction. Taxpayer-funded programs paid for the prescriptions that followed.

What Proof Do You Need as a Whistleblower?

The useful evidence connects what the company paid, what happened at the event, who benefited and why the company selected them. We work through those connections with the insider who understands the records and the decisions behind them.

The invitation identifies the planned audience. The attendee list records who the company says came. The expense report allocates the meal or travel cost, while the speaker agreement and presentation describe the service being purchased. Together, they let us examine whether the payment followed the event the company described.

Recipient information and the product field connect that event to the reported transfer. Prescribing records and government-paid claims take the inquiry beyond the event. A person in sales operations may understand the speaker-selection decision, while someone in finance can explain how the payment was coded and someone at the dinner can describe what actually happened.

Veloxis’s August 2026 corporate integrity agreement required a centralized electronic speaker-program system with comprehensive attendee lists, written speaker agreements and independently assessed payment rates. It also required live monitoring of presentations and sales-representative activity. The paperwork and the event had to face the same scrutiny.

We examine who changed the attendance, what the change did to the reported benefit and whether the company’s prescribing expectations explain the payment.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know Who Was at the Dinner

If you reconcile pharmaceutical payments or know why an attendee was added or left off, speak with our whistleblower experts about the records behind those decisions. We work with you to build your strongest whistleblower case connecting the company’s payments to its prescribing objectives, bring in pharmaceutical kickback whistleblower lawyers, and stay beside you throughout the process.